Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Commercial
  • Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool
  • Commercial

Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool

BioPharma Dive

Some 1,390 Foundayo prescriptions were written in two days, according to analysts.

CommercialMetabolic & GLP-1Read full story

pharminent April 17, 2026 (Last updated: April 17, 2026)

BioPharma Dive

Some 1,390 Foundayo prescriptions were written in two days, according to analysts.

CommercialMetabolic & GLP-1Read full story

Post navigation

Previous: Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch
Next: Kailera makes history with record-breaking $625m IPO

Related Stories

  • Commercial

Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1

pharminent August 5, 2026
  • Commercial

Leqembi sales grow again after subcutaneous approvals

pharminent July 29, 2026
  • Commercial

Wegovy pill launches in UK as first daily oral GLP1 for weight management

pharminent July 6, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.